← Research hub  ·  securities

REGN · Regeneron Pharmaceuticals $784.37 -5.08 (-0.64%) 2026-SEP-18 12:48 EST

My allocationNot heldas of 2026-SEP-03 · allocation page ↗
Research: QT · SA · STK · FA1 mention
2026-AUG-07 · CNBC · CNBC Halftime Report (audio edition) · Neutralinsight · read ↗ · source page ↗$774.47

In short: Named among Harrington's healthcare positions in the sector-rebound roll call — part of the group she describes as having been "undervalued and ignored and neglected" while producing large free cash flow. No individual call.

SOD $774.47

Nothing matches this filter.

Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.